SGMO - Sangamo Therapeutics Inc
Sangamo Therapeutics Inc Logo

SGMO - Sangamo Therapeutics Inc

https://www.sangamo.com
Momentum: Bearish
Recent News
Powered by Alpha Vantage
AI Tools
Key Metrics
Trend: Downtrend
Source: Snapshot

Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic drugs that transform the lives of patients using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company is headquartered in Brisbane, California.

52W High
$3.18
52W Low
$0.41
MA Status:
50D: Below 200D: Below
Beta (~1 neutral, <0.9 lower risk)
1.21
Valuation
As of 2025-06-30 (Overview)
Trailing P/E (<15 better)
N/A
Forward P/E (<15 better)
N/A
EV/EBITDA (<8 favorable)
-1.00
EV/Revenue (<3 favorable)
1.84
P/S (TTM) (<3 favorable)
2.02
P/B (<3 favorable)
8.42
Ownership
Retail‑heavy
Source: Overview
Insiders (1–5% typical)
2.16%
Institutions (25–75% balanced)
16.96%
Shares Outstanding
301,709,000
Float
295,141,000
Dividend Yield (2–6% sweet spot)
N/A
Ex‑Dividend Date
N/A
Income & Growth
Profitability: Weak
As of 2025-06-30 (Overview)
Revenue (TTM)
81,706,000
Gross Profit (TTM)
-22,791,000
EPS (TTM)
-0.26
Profit Margin (>10% good)
-0.78%
Operating Margin (TTM) (higher better)
-0.98%
ROE (TTM) (>15% strong)
-2.93%
EPS YoY (Quarterly) (>10% good)
N/A
Revenue YoY (Quarterly) (>8% good)
50.42
Momentum
Bearish momentum
Value
-0.0051
Previous
-0.0022
Trend
Falling
Signal Cross
No cross
As of
Sep. 12, 2025